Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

Drug combination reaches key threshold for ‘functional cure’ of chronic liver infection that affects more than 250 million ...

The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

The following is a summary of “Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study ...

US FDA grants fast track designation to Lipocine’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis: Salt Lake City Thursday, December 19, 2024, ...

Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...

One of the newer types of treatment is the TIPS procedure, which helps to reduce the portal hypertension that contributes to ascites. Ascites is the most common complication of cirrhosis.